Opportunities for Earlier Diagnosis and Treatment of Cardiac Amyloidosis
References
- Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021 Apr 21;42(16):1554-1568. doi: 10.1093/eurheartj/ehab072
- Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017 Apr 4;135(14):1357-1377. doi: 10.1161/CIRCULATIONAHA.116.024438
- Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017 Dec;84(12 Suppl 3):12-26. doi: 10.3949/ccjm.84.s3.02
- Witteles RM, Bokhari S, Damy T, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019 Aug;7(8):709-716. doi: 10.1016/j.jchf.2019.04.010
- Bianchi G, Zhang Y, Comenzo RL. AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021 Oct 19;3(4):467-487. doi: 10.1016/j.jaccao.2021.09.003
- Maurer MS, Bokhari S, Damy T, et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2019 Sep;12(9):
e006075 . doi: 10.1161/CIRCHEARTFAILURE.119.006075 - Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020 Jul 7;142(1):e7-e22. doi: 10.1161/CIR.0000000000000792
- Lane T, Fontana M, Martinez-Naharro A, et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169
- Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018 Aug 7;39(30):2799-2806. doi: 10.1093/eurheartj/ehx589
- Grogan M, Scott CG, Kyle RA, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20. doi: 10.1016/j.jacc.2016.06.033
- Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. doi: 10.1016/j.jacc.2019.04.003
- Hahn VS, Yanek LR, Vaishnav J, et al. Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. JACC Heart Fail. 2020 Sep;8(9):712-724. doi: 10.1016/j.jchf.2020.04.007
- González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015 Oct 7;36(38):2585-94. doi: 10.1093/eurheartj/ehv338
- Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232-9. doi: 10.1080/07853890701842988
- Grodin JL, Maurer MS. The Truth Is Unfolding About Transthyretin Cardiac Amyloidosis. Circulation. 2019 Jul 2;140(1):27-30. doi: 10.1161/CIRCULATIONAHA.119.041015
- Stern LK, Patel J. Cardiac Amyloidosis Treatment. Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):59-72. doi: 10.14797/mdcvj.1050
- Donnellan E, Wazni OM, Hanna M, et al. Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies. JACC Clin Electrophysiol. 2020 Sep;6(9):1118-1127. doi: 10.1016/j.jacep.2020.04.019
- Damy T, Maurer MS, Rapezzi C, et al. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart. 2016 Feb 8;3(1):
e000289 . doi: 10.1136/openhrt-2015-000289 - Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689
- Damy T, Kristen AV, Suhr OB, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). Eur Heart J. 2019 Apr 1;43(5):391-400. doi: 10.1093/eurheartj/ehz173
- Siqueira-Filho AG, Cunha CL, Tajik AJ, Seward JB, Schattenberg TT, Giuliani ER. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation. 1981 Jan;63(1):188-96. doi: 10.1161/01.cir.63.1.188
- Martyn T, Saef J, Dey AR, et al. Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function. JACC Heart Fail. 2022 Sep;10(9):689-691. doi: 10.1016/j.jchf.2022.06.006
- Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012 Oct;98(19):1442-8. doi: 10.1136/heartjnl-2012-302353
- Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018 Jan;28(1):10-21. doi: 10.1016/j.tcm.2017.07.004
- Donnellan E, Wazni O, Kanj M, et al. Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis. Europace. 2020 Feb 1;22(2):259-264. doi: 10.1093/europace/euz314
- Bukhari S, Barakat AF, Eisele YS, et al. Prevalence of Atrial Fibrillation and Thromboembolic Risk in Wild-Type Transthyretin Amyloid Cardiomyopathy. Circulation. 2021 Mar 30;143(13):1335-1337. doi: 10.1161/CIRCULATIONAHA.120.052136
- González-López E, López-Sainz Á, Garcia-Pavia P. Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope. Rev Esp Cardiol (Engl Ed). 2017 Nov;70(11):991-1004. doi: 10.1016/j.rec.2017.05.036
- Huang J, Zhao S, Chen Z, Zhang S, Lu M. Contribution of Electrocardiogram in the Differentiation of Cardiac Amyloidosis and Nonobstructive Hypertrophic Cardiomyopathy. Int Heart J. 2015;56(5):522-6. doi: 10.1536/ihj.15-005
- Sperry BW, Reyes BA, Ikram A, et al. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018 Oct 23;72(17):2040-2050. doi: 10.1016/j.jacc.2018.07.092
- Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis. JAMA. 2017 Sep 12;318(10):962-963. doi: 10.1001/jama.2017.9236
- Westermark P, Westermark GT, Suhr OB, Berg S. Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci. 2014 Aug;119(3):223-8. doi: 10.3109/03009734.2014.895786
- Stein K, Störkel S, Linke RP, Goebel HH. Chemical heterogeneity of amyloid in the carpal tunnel syndrome. Virchows Arch A Pathol Anat Histopathol. 1987;412(1):37-45. doi: 10.1007/BF00750729
- Karam C, Dimitrova D, Christ M, Heitner SB. Carpal tunnel syndrome and associated symptoms as first manifestation of hATTR amyloidosis. Neurol Clin Pract. 2019 Aug;9(4):309-313. doi: 10.1212/CPJ.0000000000000640
- Sperry BW, Khedraki R, Gabrovsek A, et al. Cardiac Amyloidosis Screening at Trigger Finger Release Surgery. Am J Cardiol. 2021 Dec 1;160:96-98. doi: 10.1016/j.amjcard.2021.08.049
- Nakagawa M, Sekijima Y, Yazaki M, et al. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016;23(1):58-63. doi: 10.3109/13506129.2015.1135792
- Hanna M, Ruberg FL, Maurer MS, et al. Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. J Am Coll Cardiol. 2020 Jun 9;75(22):2851-2862. doi: 10.1016/j.jacc.2020.04.022
- Marume K, Takashio S, Nishi M, et al. Combination of Commonly Examined Parameters Is a Useful Predictor of Positive 99 mTc-Labeled Pyrophosphate Scintigraphy Findings in Elderly Patients With Suspected Transthyretin Cardiac Amyloidosis. Circ J. 2019 Jul 25;83(8):1698-1708. doi: 10.1253/circj.CJ-19-0255
- Davies DR, Redfield MM, Scott CG, et al. A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2022 Sep 7;
e221781 . doi: 10.1001/jamacardio.2022.1781 - Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. J Card Fail. 2019 Nov;25(11):e1-e39. doi: 10.1016/j.cardfail.2019.08.001
- Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. J Card Fail. 2019 Nov;25(11):854-865. doi: 10.1016/j.cardfail.2019.08.002
- Rapezzi C, Elliott P, Damy T, et al. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. JACC Heart Fail. 2021 Feb;9(2):115-123. doi: 10.1016/j.jchf.2020.09.011
- Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153
- Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793
- Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021 Aug 5;385(6):493-502. doi: 10.1056/NEJMoa2107454
- Martyn T, Saef J, Hussain M, et al. The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era. J Card Fail. 2022 Jul 14;S1071-9164(22)00581-4. doi: 10.1016/j.cardfail.2022.06.005
- Nativi-Nicolau J, Siu A, Dispenzieri A, et al. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC CardioOncol. 2021 Oct 19;3(4):537-546. doi: 10.1016/j.jaccao.2021.08.009
- Poterucha TJ, Elias P, Bokhari S, et al. Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution. JACC Cardiovasc Imaging. 2021 Jun;14(6):1221-1231. doi: 10.1016/j.jcmg.2020.08.027
- Donnelly JP, Hanna M, Sperry BW, Seitz WH
Jr . Carpal Tunnel Syndrome: A Potential Early, Red-Flag Sign of Amyloidosis. J Hand Surg Am. 2019 Oct;44(10):868-876. doi: 10.1016/j.jhsa.2019.06.016 - Hussain M, Sperry BW, Hanna M, Jaber WA. Conversion of 99mtechnetium-pyrophosphate scintigraphy in a patient with hereditary ATTR amyloidosis: importance of repeat scanning. Eur Heart J Case Rep. 2020 Nov 9;4(6):1-2. doi: 10.1093/ehjcr/ytaa386
- Westin O, Fosbøl EL, Maurer MS, et al. Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome. J Am Coll Cardiol. 2022 Sep 6;80(10): 967-977. doi: 10.1016/j.jacc.2022.06.026
- Godara A, Riesenburger RI, Zhang DX, et al. Association between spinal stenosis and wild-type ATTR amyloidosis. Amyloid. 2021 Dec;28(4):226-233. doi: 10.1080/13506129.2021.1950681
- Yanagisawa A, Ueda M, Sueyoshi T, et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol. 2015 Feb;28(2):201-7. doi: 10.1038/modpathol.2014.102
- Maurer MS, Smiley D, Simsolo E, et al. Analysis of lumbar spine stenosis specimens for identification of amyloid. J Am Geriatr Soc. 2022 Aug 5. doi: 10.1111/jgs.17976
- Nitsche C, Scully PR, Patel KP, et al. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. J Am Coll Cardiol. 2021 Jan 19;77(2):128-139. doi: 10.1016/j.jacc.2020.11.006
- DeFilippis EM, Beale A, Martyn T, et al. Heart Failure Subtypes and Cardiomyopathies in Women. Circ Res. 2022 Feb 18;130(4):436-454. doi: 10.1161/CIRCRESAHA.121.319900
- Sperry BW, Hanna M, Shah SJ, Jaber WA, Spertus JA. Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT. JACC Heart Fail. 2021 Nov;9(11):795-802. doi: 10.1016/j.jchf.2021.06.007
- Oghina S, Bougouin W, Bézard M, et al. The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials. JACC Heart Fail. 2021 Mar;9(3):169-178. doi: 10.1016/j.jchf.2020.12.005
- Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017 Oct 7;38(38):2879-2887. doi: 10.1093/eurheartj/ehx350
- Scully PR, Patel KP, Treibel TA, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020 Aug 1;41(29):2759-2767. doi: 10.1093/eurheartj/ehaa170
- Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015 Jan 1;372(1):21-9. doi: 10.1056/NEJMoa1404852
- Coniglio AC, Segar MW, Loungani RS, et al. Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults. JACC Heart Fail. 2022 Feb;10(2):129-138. doi: 10.1016/j.jchf.2021.09.006
- Sinha A, Zheng Y, Nannini D, et al. Association of the V122I Transthyretin Amyloidosis Genetic Variant With Cardiac Structure and Function in Middle-aged Black Adults: Coronary Artery Risk Development in Young Adults (CARDIA) Study. JAMA Cardiol. 2020 Dec 23;6(6):1-5. doi: 10.1001/jamacardio.2020.6623
- ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2022.
Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations (SCAN-MP) ; 2022 May 23 [cited 2022 Nov 17]. Available from:https://clinicaltrials.gov/ct2/show/NCT03812172 - AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021 Nov 1;6(11):1267-1274. doi: 10.1001/jamacardio.2021.3070
- Huda A, Castaño A, Niyogi A, et al. A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. Nat Commun. 2021 May 11;12(1):2725. doi: 10.1038/s41467-021-22876-9
- Narang A, Bae R, Hong H, et al. Utility of a Deep-Learning Algorithm to Guide Novices to Acquire Echocardiograms for Limited Diagnostic Use. JAMA Cardiol. 2021 Jun 1;6(6):624-632. doi: 10.1001/jamacardio.2021.0185
- Zhang J, Gajjala S, Agrawal P, et al. Fully Automated Echocardiogram Interpretation in Clinical Practice. Circulation. 2018 Oct 16;138(16):1623-1635. doi: 10.1161/CIRCULATIONAHA.118.034338
- Grogan M, Lopez-Jimenez F, Cohen-Shelly M, et al. Artificial Intelligence-Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis. Mayo Clin Proc. 2021 Nov;96(11):2768-2778. doi: 10.1016/j.mayocp.2021.04.023
- Goto S, Mahara K, Beussink-Nelson L, et al. Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. Nat Commun. 2021 May 11;12(1):2726. doi: 10.1038/s41467-021-22877-8
- Reza N, Damrauer SM. Toward Population-Based Genetic Screening for Hereditary Amyloidosis. JACC CardioOncol. 2021 Oct 19;3(4):562-564. doi: 10.1016/j.jaccao.2021.09.005
- Parker MM, Damrauer SM, Tcheandjieu C, et al. Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry. Sci Rep. 2021 Jun 2;11(1):
11645 . doi: 10.1038/s41598-021-91113-6 - Damrauer SM, Chaudhary K, Cho JH, et al. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry. JAMA. 2019 Dec 10;322(22):2191-2202. doi: 10.1001/jama.2019.17935
- Jiang X, Labaudinière R, Buxbaum JN, et al. A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):
e2016072118 . doi: 10.1073/pnas.2016072118 - ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2022.
Monitorial of Early Disease Progression in hereditary Transthyretin Amyloidosis (MED-hATTR) ; 2022 Mar 28 [cited 2022 Nov 11]. Available from:https://www.clinicaltrials.gov/ct2/show/NCT03431896 - Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2017 Jul 25;70(4):466-477. doi: 10.1016/j.jacc.2017.05.053
DOI: https://doi.org/10.14797/mdcvj.1163 | Journal eISSN: 1947-6108
Language: English
Page range: 27 - 39
Submitted on: Sep 19, 2022
Accepted on: Oct 7, 2022
Published on: Dec 6, 2022
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
© 2022 Trejeeve Martyn, Andres Carmona Rubio, Jerry D. Estep, Mazen Hanna, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.